Source comparison
11. TB-500 vs full-length TB-4
TB-500 (synthetic active-region analogue) and full-length recombinant TB-4 differ in: Size and molecular weight: TB-500 is a shorter peptide (typically ~17 amino acids vs TB-4’s 43). G-actin binding affinity: the full-length peptide has higher actin affinity;
This comparison does not assign a generated winner or score.
- TB-500 (synthetic active-region analogue) and full-length recombinant TB-4 differ in:
- Size and molecular weight: TB-500 is a shorter peptide (typically ~17 amino acids vs TB-4’s 43).
- G-actin binding affinity: the full-length peptide has higher actin affinity; the active-region analogue retains biological activity but may bind actin less tightly.
- Manufacturing: TB-500 is chemically synthesised; TB-4 can be recombinantly produced.
- Pharmacokinetics: the two may have different stability and clearance profiles.
- For most research applications, TB-500 is treated as a functional analogue of TB-4 — the convention in the research-grade peptide space.